Emma Rose Holbrook

Emma Holbrook practices at Sharp Grossmont Hospital in La Mesa, California, part of Sharp HealthCare.

Emma Holbrook's NPI, 1255087102, was assigned on March 1, 2022.

Emma Holbrook's primary practice is Sharp Grossmont Hospital, at 5555 Grossmont Center Drive Box 58, La Mesa, CA 91942 in San Diego County. The practice phone is (619) 465-0711.

Emma Holbrook's primary practice is Sharp Grossmont Hospital in La Mesa, California, part of Sharp HealthCare. The medical group on file is Emergency and Acute Care Medical Corporation. Dmand AI also links Emma Holbrook to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Emma Holbrook practices. Vendor and product names are available with a free account.

Physician assistant is Emma Holbrook's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Dmand AI has Emma Holbrook's licenses on file in 2 states: Arizona and California.

CMS data shows 5,088 Medicare services from Emma Holbrook across 8 procedure codes in 2024, for 1,203 Medicare patients. Medicare paid $238,819 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 1,203 Medicare patients who saw Emma Holbrook in 2024. The largest group is 65 to 74, with 399 patients. 75% of them have high blood pressure, and 75% have mood disorders. 89% are also on Medicaid. Their average risk score is 2.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Emma Holbrook's median patient age at 65, with 62% women.

In 2024, Emma Holbrook wrote 538 Medicare Part D claims for 83 patients. 94% of them were for generic drugs. CMS names the drug for 298 of them, across 16 drugs with 11 or more claims each, at $5,140 in total drug cost.

Emma Holbrook accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Emma Holbrook from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. MAQUET Cardiovascular U.S. Sales, L.L.C. paid the most, $57.